OMEROS CORP (OMER) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 124.83M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $124.83M | (m) |
| 2026-03-31 | (m) | $86.17M | (m) |
| 2025-12-31 | (m) | $-3.35M | (m) |
| 2025-09-30 | (m) | $-121.16M | (m) |
| 2025-06-30 | (m) | $-122.47M | (m) |
| 2025-03-31 | (m) | $-153.09M | (m) |
| 2024-12-31 | (m) | $-156.81M | (m) |
| 2024-09-30 | (m) | $-134.53M | (m) |
| 2024-06-30 | (m) | $-140.04M | (m) |
| 2024-03-31 | (m) | $-121.30M | (m) |
| 2023-12-31 | (m) | $-117.81M | (m) |
| 2023-09-30 | (m) | $19.99M | (m) |
| 2023-06-30 | (m) | $40.28M | (m) |
| 2023-03-31 | (m) | $46.73M | (m) |
| 2022-12-31 | (m) | $47.42M | (m) |
| 2022-09-30 | (m) | $199.31M | (m) |
| 2022-06-30 | (m) | $194.06M | (m) |
| 2022-03-31 | (m) | $196.31M | (m) |
| 2021-12-31 | (m) | $194.24M | (m) |
| 2021-09-30 | (m) | $-123.66M | (m) |
| 2021-06-30 | (m) | $-139.42M | (m) |
| 2021-03-31 | (m) | $-144.12M | (m) |
| 2020-12-31 | (m) | $-138.06M | (m) |
| 2020-09-30 | (m) | $-130.01M | (m) |
| 2020-06-30 | (m) | $-108.01M | (m) |
| 2020-03-31 | (m) | $-89.17M | (m) |
| 2019-12-31 | (m) | $-84.49M | (m) |
| 2019-09-30 | (m) | $-78.80M | (m) |
| 2019-06-30 | (m) | $-101.81M | (m) |
| 2019-03-31 | (m) | $-121.05M | (m) |
| 2018-12-31 | (m) | $-126.76M | (m) |
| 2018-09-30 | (m) | $-119.79M | (m) |
| 2018-06-30 | (m) | $-87.80M | (m) |
| 2018-03-31 | (m) | $-68.47M | (m) |
| 2017-12-31 | (m) | $-53.48M | (m) |
| 2017-09-30 | (m) | $-56.52M | (m) |
| 2017-06-30 | (m) | $-63.00M | (m) |
| 2017-03-31 | (m) | $72.15M | (m) |
| 2016-12-31 | (m) | $-66.75M | (m) |
| 2016-09-30 | (m) | $-66.94M | (m) |
| 2016-06-30 | (m) | $-72.90M | (m) |
| 2016-03-31 | (m) | $-76.97M | (m) |
| 2015-12-31 | (m) | $-75.10M | (m) |
| 2015-09-30 | (m) | $-75.98M | (m) |
| 2015-06-30 | (m) | $-74.39M | (m) |
| 2015-03-31 | (m) | $-75.70M | (m) |
| 2014-12-31 | (m) | $-73.67M | (m) |
| 2014-09-30 | (m) | $-54.80M | (m) |
| 2014-06-30 | (m) | $-50.35M | (m) |
| 2014-03-31 | (m) | $-45.95M | (m) |
| 2013-12-31 | (m) | $-39.80M | (m) |
| 2013-09-30 | (m) | $-45.69M | (m) |
| 2013-06-30 | (m) | $-45.09M | (m) |
| 2013-03-31 | (m) | $-40.04M | (m) |
| 2012-12-31 | (m) | $-38.44M | (m) |
| 2012-09-30 | (m) | $-40.91M | (m) |
| 2012-06-30 | (m) | $-34.15M | (m) |
| 2012-03-31 | (m) | $-30.90M | (m) |
| 2011-12-31 | (m) | $-28.55M | (m) |
| 2011-09-30 | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) |
| 2010-12-31 | (m) | $-29.25M | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
| 2009-12-31 | (m) | $-21.09M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |